(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Safi advancing manufactured human RBC (mRBC) program for acute bleeding and chronic transfusion indications This DoD award acceler ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

The drugs show pharma at its best and its worst: drugs such as Vertex's ... the majority of FDA expert sentiment being against it, and such was the case with Sprout Pharmaceuticals' Addyi ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

It later moved into medicines, commercialising aspirin around the turn of the 20th century, one of the most successful pharmaceuticals ... and Drug Administration (FDA) rules demanding proof ...